| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
Antibacterial; coccidiostat; feed additives
|
|---|---|
| ln Vitro |
It is thought that monensin increases the efficiency of feed utilization by cattle by altering the rumen fermentation. We studied the effect of monensin and the related ionophore antibiotic lasalocid-sodium (Hoffman-LaRoche) on the growth of methanogenic and rumen saccharolytic bacteria in a complex medium containing rumen fluid. Ruminococcus albus, Ruminococcus flavefaciens, and Butyrivibrio fibrisolvens were inhibited by 2.5 mug of monensin or Lasalocid per ml. Growth of Bacteroides succinogenes and Bacteroides ruminicola was delayed by 2.5 mug of monensin or Lasalocid per ml. Populations of B. succinogenes and B. ruminicola that were resistant to 20 mug of either drug per ml were rapidly selected by growth in the presence of each drug at 5.0 mug/ml. Selenomonas ruminantium was insensitive to 40 mug of monensin or Lasalocid per ml. Either antibiotic (10 mug/ml) inhibited Methanobacterium MOH, Methanobacterium formicicum, and Methanosarcina barkeri MS. Methanobacterium ruminantium PS was insensitive to 40 mug of monensin or 20 mug of Lasalocid per ml. The methanogenic strain 442 was insensitive to 40 mug of monensin but sensitive to 10 mug of Lasalocid per ml. The results suggest that monensin or Lasalocid acts in the rumen by selecting for succinate-forming Bacteroides and for S. ruminantium, a propionate producer that decarboxylates succinate to propionate. The selection could lead to an increase in rumen propionate formation. Selection against H(2) and formate producers, e.g. R. albus, R. flavefaciens, and B. fibrisolvens, could lead to a depression of methane production in the rumen[1].
|
| Toxicity/Toxicokinetics |
rat LD50 oral 122 mg/kg Veterinary and Human Toxicology., 26(322), 1984 [PMID:6380094]
mouse LD50 oral 146 mg/kg CRC Handbook of Antibiotic Compounds, Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980, 5(502), 1981 mouse LD50 intraperitoneal 40 mg/kg Antibiotics: Origin, Nature, and Properties, Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978, 1(809), 1978 rabbit LD50 oral 40 mg/kg Veterinary and Human Toxicology., 26(322), 1984 [PMID:6380094] chicken LD50 oral 72 mg/kg Veterinary and Human Toxicology., 26(322), 1984 [PMID:6380094] |
| References |
[1]. Appl Environ Microbiol
. 1979 Jul;38(1):72-7. doi: 10.1128/aem.38.1.72-77.1979.
|
| Additional Infomation |
Lasalocid is a polyether antibiotic used for prevention and treatment of coccidiosis in poultry. It has a role as a coccidiostat, a bacterial metabolite and an ionophore. It is a monohydroxybenzoic acid, a beta-hydroxy ketone, a secondary alcohol, a member of oxolanes, a monocarboxylic acid, a member of oxanes, a tertiary alcohol and a polyether antibiotic. It is a conjugate acid of a lasalocid(1-).
Lasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of Streptomyces lasaliensis. Lasalocid has been reported in Streptomyces with data available. Cationic ionophore antibiotic obtained from Streptomyces lasaliensis that, among other effects, dissociates the calcium fluxes in muscle fibers. It is used as a coccidiostat, especially in poultry. See also: Lasalocid Sodium (has salt form); Bacitracin Zinc; Lasalocid (component of); Bambermycins; Lasalocid (component of) ... View More ... |
| Molecular Formula |
C34H54O8
|
|---|---|
| Molecular Weight |
590.7878
|
| Exact Mass |
590.381
|
| Elemental Analysis |
C, 69.12; H, 9.21; O, 21.66
|
| CAS # |
25999-31-9
|
| Related CAS # |
Lasalocid sodium;25999-20-6; 62211-64-7 (anion); 73951-77-6 (acetate); 25999-31-9 (free); 83198-76-9 (potassium)
|
| PubChem CID |
5360807
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
735.7±60.0 °C at 760 mmHg
|
| Flash Point |
224.8±26.4 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.529
|
| LogP |
6.55
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
42
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O1[C@]([H])([C@]([H])(C([C@@]([H])(C([H])([H])[H])[C@]([H])([C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])C2C([H])=C([H])C(C([H])([H])[H])=C(C=2C(=O)O[H])O[H])O[H])=O)C([H])([H])C([H])([H])[H])[C@@]([H])(C([H])([H])[H])C([H])([H])[C@@]1(C([H])([H])C([H])([H])[H])[C@@]1([H])C([H])([H])C([H])([H])[C@](C([H])([H])C([H])([H])[H])([C@]([H])(C([H])([H])[H])O1)O[H]
|
| InChi Key |
BBMULGJBVDDDNI-OWKLGTHSSA-N
|
| InChi Code |
InChI=1S/C34H54O8/c1-9-25(31-21(6)18-34(11-3,42-31)26-16-17-33(40,10-2)23(8)41-26)30(37)22(7)28(35)19(4)12-14-24-15-13-20(5)29(36)27(24)32(38)39/h13,15,19,21-23,25-26,28,31,35-36,40H,9-12,14,16-18H2,1-8H3,(H,38,39)/t19-,21+,22+,23+,25+,26-,28+,31+,33-,34+/m1/s1
|
| Chemical Name |
6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid
|
| Synonyms |
lasalocid; Lasalocid A; 25999-31-9; Lasalocide; Antibiotic X 537A; Lasalocido; Lasalocidum; Lasalocide A;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~169.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6926 mL | 8.4632 mL | 16.9265 mL | |
| 5 mM | 0.3385 mL | 1.6926 mL | 3.3853 mL | |
| 10 mM | 0.1693 mL | 0.8463 mL | 1.6926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
